Skip to main content
Signal8

ACR 2026: Dapirolizumab Pegol Associated with Greater Treatment Response Rates Versus Placebo in SLE Using Novel Treatment Response Measure

$BIIBPress releaseNov 9, 2026, 1:00 AM ET

UCB and Biogen presented five posters at ACR Convergence 2026 showing dapirolizumab pegol outperformed placebo plus standard of care across novel and sustained-response endpoints in the Phase 3 PHOENYCS GO lupus study. In the first application of the new TRM-SLE measure to the data, 61.2% of DZP patients achieved TRM-SLE-50 response versus 43.2% on placebo, and 52.5% achieved TRM-SLE-100 versus 36.8%, through Week 48. Separate post-hoc analyses showed roughly double the rates of sustained low disease activity (24.0% vs 10.3%) and higher sustained remission (11.5% vs 4.7%) versus placebo, all nominally significant.

Key figures

Drug Name
dapirolizumab pegol (DZP)
Phase Of Trial
Phase 3
Bicla
50% (103/208) vs 35% (37/107); p=0.011
Sri 4
60% (125/208) vs 41% (44/107)
Trm sle 50
61.2% vs 43.2% (DZP+SOC vs placebo+SOC)
Trm sle 100
52.5% vs 36.8%
Sustained doris
11.5% vs 4.7%; nominal p=0.0253
Sustained lldas
24.0% vs 10.3%; nominal p=0.0012
Sustained lldas 5
19.2% vs 5.6%; nominal p=0.0002

AI analysis

Red flags3 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.

    BIIB: ACR 2026: Dapirolizumab Pegol Associated with Greater Treatment Response Rates Versus Placebo in SLE Using Novel Treatment Response Measure — AI Analysis | Signal8